PF-06842874 / Pfizer - LARVOL DELTA

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants (clinicaltrials.gov) - P1; N=44; Completed; Sponsor: Pfizer; Recruiting ➔ Completed; N=98 ➔ 44; Trial completion date: Jan 2022 ➔ Jul 2021; Trial primary completion date: Jan 2022 ➔ Jul 2021

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants (clinicaltrials.gov) - P1; N=98; Recruiting; Sponsor: Pfizer; Trial completion date: Oct 2021 ➔ Jan 2022; Trial primary completion date: May 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial primary completion date

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants (clinicaltrials.gov) - P1; N=98; Recruiting; Sponsor: Pfizer; Trial completion date: Dec 2020 ➔ Oct 2021; Trial primary completion date: Dec 2020 ➔ May 2021

Clinical • Trial completion date • Trial primary completion date • ALB

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants (clinicaltrials.gov) - P1; N=98; Recruiting; Sponsor: Pfizer; Not yet recruiting ➔ Recruiting; N=36 ➔ 98; Trial completion date: Feb 2020 ➔ Nov 2020; Trial primary completion date: Feb 2020 ➔ Nov 2020

Clinical • Enrollment change • Enrollment open • Trial completion date • Trial primary completion date